Results 61 to 70 of about 978,166 (202)

Reduced DNA methylation and hydroxymethylation in patients with systemic mastocytosis [PDF]

, 2015
Objective: As disruption of epigenetic control is a frequent event in solid tumors and leukemia, we investigated changes in DNA methylation (5mC) and hydroxymethylation (5hmC) in patients with systemic mastocytosis (SM), a rare myeloproliferative disease
Ester M. Orlandi, Angelo V. Marzano, Serena Merante, Giovanna De Matteis, Silvia Monticelli, Sara Montagner, Rocco D'Antuono, Roberta Zanotti, Lorenzo Deho', Cristina Leoni, Zanotti R, Marzano AV, Deho' L, De Matteis G, Orlandi EM, D'Antuono R, Montagner S, Monticelli S, Montagner, Sara, Leoni, Cristina, Leoni C, Merante S   +21 more
core   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

European Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Drug hypersensitivity reactions and allergy in patients with mastocytosis [PDF]

, 2017
Mastocytosis is a rare myeloproliferative disease caused by excessive proliferation and accumulation of mast cells in the skin and internal organs. The most common variant of mastocytosis in children is cutaneous mastocytosis.
Barbara Kwiecińska, Roman Nowicki, Hanna Ługowska-Umer, Justyna H. Czarny, Marek B. Niedoszytko, Monika Sikorska, Magdalena Lange, Aleksandra Górska   +7 more
core   +1 more source

Post‐Hoc Long‐Read Sequencing Links Leukemic Mutation Status to Single‐Cell Transcriptomes

European Journal of Haematology, EarlyView.
ABSTRACT Single‐cell RNA‐sequencing‐based characterization of cells that belong to the neoplastic clone is a major challenge in hematologic neoplasms, where malignant and normal cells coexist. Confident molecular profiling requires simultaneous analysis of gene expression and genetic mutations in individual cells, an ability that is not supported by ...
Sofia Papavasileiou, Chenyan Wu, Daryl Boey, Lucille Margerie, Jiezhen Mo, Ulla Olsson‐Strömberg, Stina Söderlund, Gunnar Nilsson, Joakim S. Dahlin   +8 more
wiley   +1 more source

Case Report: Treatment of systemic mastocytosis with sunitinib [version 1; referees: 2 approved]

F1000Research, 2017
Mast cell activation disease typically presents as chronic multisystem polymorbidity of generally inflammatory ± allergic theme.  Presently, treatment of the rare, cytoproliferative variant systemic mastocytosis employs empirically selected therapies to ...
Gerhard J. Molderings, Lawrence B. Afrin, Hans-Jörg Hertfelder, Stefan Brettner   +3 more
doaj   +1 more source

ICSH Guidance on Bone Marrow Examination and Reporting

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease
Wendy N. Erber, Alexandar Tzankov, Olga Pozdnyakova, Hiromichi Matsushita, Gina Zini, Leonie Saft, on behalf of the International Council for Standardization in Haematology   +6 more
wiley   +1 more source

Systemic Mastocytosis Presenting as Acute Appendicitis: A Case Report and Review of the Literature

Case Reports in Oncology, 2013
Systemic mastocytosis is characterized by abnormal growth and accumulation of mast cells in various organs. Gastrointestinal (GI) symptoms are common disease manifestations in this disease and can significantly impair the quality of life.
Syed A. Akbar, Shahzad Raza, Jason E. Denney, Eric J. Johannesen, Donald C. Doll   +4 more
doaj   +1 more source

Combination of Hypofractionated Radiation Therapy and Gilvetmab for the Treatment of Cutaneous or Subcutaneous Mast Cell Tumours in Dogs

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Gilvetmab is a caninised monoclonal antibody against canine PD‐1. Concurrent or sequential administration of anti‐PD‐1 antibodies and radiation therapy (RT) improves survival time in various species. Eighteen dogs with mast cell tumours (MCTs) were prospectively treated with 24 Gy of RT over Days 0, 7 and 21 and gilvetmab every 2 weeks ...
Tiffany W. Martin, Douglas H. Thamm, Kristen M. Weishaar   +2 more
wiley   +1 more source

Algorithms in Allergy: Treatment of Hypereosinophilic Syndromes, 2026 Update

Allergy, EarlyView.
Guillaume Lefèvre, Florence Roufosse, Giacomo Emmi, Andreas Reiter, Emmanuel Ledoult, Jean‐Emmanuel Kahn   +5 more
wiley   +1 more source

Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis

Haematologica, 2011
Cooperating genetic events are likely to contribute to the phenotypic diversity of KIT-D816V systemic mastocytosis. In this study, 44 patients with KIT-D816V systemic mastocytosis were evaluated for coexisting NRAS, KRAS, HRAS or MRAS mutations ...
Todd M. Wilson, Irina Maric, Olga Simakova, Yun Bai, Eunice Ching Chan, Nicolas Olivares, Melody Carter, Dragan Maric, Jamie Robyn, Dean D. Metcalfe   +9 more
doaj   +1 more source